| [1] |
Li Z,Li Y,Chen Y,et al. Trends of pulmonary fungal infections from 2013 to 2019:an AI-based real-world observational study in Guangzhou, China[J].Emerg Microbes Infect,2021,10(1):450-460.
|
| [2] |
Seagle E E,Williams S L,Chiller T M.Recent trends in the epidemiology of fungal infections[J].Infect Dis Clin N Am,2021,35(2):237-260.
|
| [3] |
Bitar D,Lortholary O,Le Strat Y,et al.Population-based analysis of invasive fungal infections,France,2001-2010[J]. Emerg Infect Dis,2014,20(7):1149-1155.
|
| [4] |
中华医学会血液学分会抗感染学组.艾沙康唑临床应用专家共识[J].临床血液学杂志,2023,36(5):295-302.
|
| [5] |
Firacative C.Invasive fungal disease in humans:are we aware of the real impact?[J].Mem Inst Oswaldo Cruz,2020,115:e200430.
|
| [6] |
Cornely O A,Alastruey I A,Arenz D,et al.Global guideline for the diagnosis and management of mucormycosis:an initiative of the European Confederation of Medical Mycology in cooperation with the mycoses study group education and research consortium[J]. Lancet Infect Dis,2019,19(12):e 405-e421.
|
| [7] |
Pagano L,Cattaneo C,Quattrone M,et al.Isavuconazole-animal data and clinical data[J].J Fungi(Basel),2020, 6(4):209.
|
| [8] |
Dagher H,Hachem R,Chaftari A,et al.Real-world use of isavuconazole as primary therapy for invasive fungal infections in high-risk patients with hematologic malignancy or stem cell transplant[J].J Fungi(Basel),2022,8(1):74.
|
| [9] |
Hassouna H,Athans V,Brizendine K D.Real-world use-Isavuconazole at a large academic medical center[J]. Mycoses,2019,62(6):534-541.
|
| [10] |
2022年01月05日药品批准证明文件待领取信息发布[EB/OL].(2022-01-05)[2024-03-06]. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20220105143701157.html.
|
| [11] |
Jenks J D,Metha S R,Hoenigl M.Broad spectrum triazoles for invasive mould infections in adults: which drug and when?[J].Med Mycol,2019,57(Suppl 2): S168-S178.
|
| [12] |
Ananda-Rajah M R,Kontoyiannis D. Isavuconazole:a new extended spectrum triazole for invasive mold dis- eases[J].Future Microbiol,2015,10(5):693-708.
|
| [13] |
Ellsworth M,Ostrosky-Zeichner L.Isavuconazole:mechanism of action,clinical efficacy and resistance[J]. J Fungi (Basel),2020,6(4):324.
|
| [14] |
闫美玲,贺 健,秦寅鹏,等.艾沙康唑诱发的水肿反应特点[J].山东医药,2024,64(2):83-85.
|
| [15] |
江英骙,朱利平.新型抗真菌药艾沙康唑的研究进展[J].药学进展,2021,45(6):427-432.
|
| [16] |
柴 双,展敬伦.5 种三唑类抗真菌药物的药物不良反应分析[J].药物不良反应,2022,38(17):2079-2083.
|
| [17] |
马 昱,王晓锋,张建萍.艾沙康唑致药源性谵妄1例[J/OL]医药导报. (2024-01-24)[2024-03-06] https://link.cnki.net/urlid/42.1293.R.20240124.1313.019.
|
| [1] |
. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(9): 789-790. |
|
|
|
2024, Vol. 35 
